The pneumococcal vaccine protects against infections caused by Streptococcus pneumoniae, a type of bacteria responsible for pneumonia, meningitis, bloodstream infections, and ear infections. There are four pneumococcal vaccines available in the United States, each targeting a different number of bacterial strains. Most children receive the vaccine as part of their routine immunization schedule, and adults 65 and older or those with certain medical conditions are also recommended to get vaccinated.
What Pneumococcal Disease Actually Does
Pneumococcal bacteria can cause a wide range of illness, from relatively mild infections like sinusitis and ear infections to life-threatening conditions. The most serious forms, collectively called invasive pneumococcal disease, include pneumonia with bloodstream infection, meningitis (infection of the membranes surrounding the brain and spinal cord), and bacteremia (bacteria circulating in the blood without a clear source). Pneumococcal bacteria are also found in about 25% to 31% of middle ear fluid samples from children with acute ear infections.
Children under five carry the highest burden worldwide, with mortality rates peaking at roughly 23.5 per 100,000 in that age group. Older adults are also at significant risk, particularly those over 65 or those with weakened immune systems.
Types of Pneumococcal Vaccines
The four available vaccines fall into two categories: conjugate vaccines and polysaccharide vaccines. The number in each vaccine’s name tells you how many bacterial strains it covers.
- PCV15 (Vaxneuvance): A conjugate vaccine covering 15 strains
- PCV20 (Prevnar 20): A conjugate vaccine covering 20 strains
- PCV21 (Capvaxive): A conjugate vaccine covering 21 strains
- PPSV23 (Pneumovax 23): A polysaccharide vaccine covering 23 strains
These aren’t interchangeable. Each one protects against a specific combination of strains, and the type your doctor recommends depends on your age, health history, and what vaccines you’ve already received.
How Conjugate and Polysaccharide Vaccines Differ
The distinction between these two vaccine types matters because they train the immune system in fundamentally different ways. Polysaccharide vaccines (PPSV23) present pieces of the bacteria’s outer coating directly to immune cells. This triggers a relatively simple immune response that produces antibodies but doesn’t build strong long-term memory. It also doesn’t work well in young children, whose immune systems aren’t mature enough to respond to this type of vaccine.
Conjugate vaccines (PCV15, PCV20, PCV21) attach those same outer coating fragments to a carrier protein. That protein acts as a signal that activates a deeper layer of the immune system, producing stronger antibodies and, crucially, creating memory cells that can respond quickly if you encounter the real bacteria later. This is why conjugate vaccines work well in infants and tend to provide more durable protection across all age groups.
Who Should Get Vaccinated
Children
The standard recommendation for children is a four-dose series of a conjugate vaccine (PCV15 or PCV20), given at 2 months, 4 months, 6 months, and between 12 and 15 months of age. This schedule aligns with other routine childhood vaccines, so it typically doesn’t require extra visits.
Adults
All adults 65 and older who haven’t previously received a pneumococcal conjugate vaccine are recommended to get one. Younger adults with certain medical conditions should also be vaccinated. These conditions include:
- Cerebrospinal fluid leak
- Cochlear implant
- Chronic liver disease
- Diabetes
- Sickle cell disease or other hemoglobin disorders
- HIV infection
- Conditions treated with immunosuppressive drugs or radiation
- Congenital or acquired immune deficiency
- Missing or nonfunctional spleen
For people with an immunocompromising condition, a cochlear implant, or a cerebrospinal fluid leak, the timeline can be accelerated, with doses given as little as eight weeks apart. These individuals may also need a follow-up dose of PCV20 or PCV21 at least five years after their most recent pneumococcal vaccination.
How Well the Vaccine Works
Pneumococcal conjugate vaccines have been one of the major success stories in childhood immunization, dramatically reducing rates of invasive pneumococcal disease since they were first introduced. In adults, the picture is more nuanced.
A real-world study of PCV20 in adults 65 and older found that vaccine effectiveness against invasive pneumococcal disease was about 35% in adults aged 65 to 74, dropping to 24% in those 75 to 84 and roughly 17% in those 85 and older. Against pneumonia requiring hospitalization, effectiveness ranged from about 20% in the youngest group to 12.5% in the oldest. These numbers are lower than what many people expect, but they still translate to meaningful protection at a population level, particularly considering how common and dangerous pneumococcal pneumonia is in older adults. Protection is strongest in the years immediately following vaccination and in younger, healthier recipients.
Side Effects
Most side effects are mild and resolve within a day or two. The most commonly reported reactions include soreness, redness, or swelling at the injection site, along with limited movement of the injected arm. Systemic reactions like fatigue, headache, fever, chills, muscle pain, joint pain, and decreased appetite can also occur but are generally short-lived. Studies comparing conjugate and polysaccharide vaccines in adults over 50 found similar side effect profiles for both types.
Serious adverse events are rare. Monitoring data from the earliest conjugate vaccine (PCV7) found that the vast majority of reported events were minor, consisting mostly of fever, rash, and local reactions at the injection site.
If You’ve Already Had a Pneumococcal Vaccine
Because newer conjugate vaccines cover more strains than earlier versions, many adults who received an older pneumococcal vaccine may benefit from an updated one. If you previously received PPSV23 or an older conjugate vaccine like PCV13, your doctor can determine whether you’re now eligible for PCV20 or PCV21 based on your age, medical conditions, and how long it’s been since your last dose. For people in the highest-risk categories, a dose of PCV20 or PCV21 is recommended at least five years after the most recent pneumococcal vaccination.